메뉴 건너뛰기




Volumn 12, Issue 8, 2012, Pages 982-987

Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer

Author keywords

Angiogenesis; Bevacizumab; BIBF 1120; Pazopanib; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; GEMCITABINE; INTERFERON; NINTEDANIB; PACLITAXEL; PAZOPANIB; SORAFENIB; TREBANANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

EID: 84866373227     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650020     Document Type: Article
Times cited : (4)

References (50)
  • 2
    • 16244403039 scopus 로고    scopus 로고
    • Cancer incidence and mortality in Europe 2004
    • Boyle, P.; Ferlay, J. Cancer incidence and mortality in Europe 2004. Ann. Oncol., 2005, 16(3), 481-488.
    • (2005) Ann. Oncol , vol.16 , Issue.3 , pp. 481-488
    • Boyle, P.1    Ferlay, J.2
  • 7
    • 77951784627 scopus 로고    scopus 로고
    • Ovarian cancer pathogenesis: A model in evolution
    • Karst, A.M.; Drapkin, R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol., 2010, 2010, 932371.
    • (2010) J. Oncol , vol.2010 , pp. 932371
    • Karst, A.M.1    Drapkin, R.2
  • 8
    • 65949104847 scopus 로고    scopus 로고
    • Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas
    • Kuo, K.T.; Guan, B.; Feng, Y.; Mao, T.L.; Chen, X.; Jinawath, N.; Wang, Y.; Kurman, R.J.; Shih, I.M., Wang, TL. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res., 2009, 69(9), 4036-4042.
    • (2009) Cancer Res , vol.69 , Issue.9 , pp. 4036-4042
    • Kuo, K.T.1    Guan, B.2    Feng, Y.3    Mao, T.L.4    Chen, X.5    Jinawath, N.6    Wang, Y.7    Kurman, R.J.8    Shih, I.M.9    Wang, T.L.10
  • 9
    • 56749103412 scopus 로고    scopus 로고
    • The cell of origin of ovarian epithelial tumours
    • Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol., 2008, 9(12), 1191-1197.
    • (2008) Lancet Oncol , vol.9 , Issue.12 , pp. 1191-1197
    • Dubeau, L.1
  • 11
    • 34347347175 scopus 로고    scopus 로고
    • The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: Amorphologic and molecular genetic analysis
    • Dehari, R.; Kurman, R.J.; Logani, S; Shih, I.M. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: amorphologic and molecular genetic analysis. Am. J. Surg. Pathol., 2007, 31(7), 1007-1112.
    • (2007) Am. J. Surg. Pathol , vol.31 , Issue.7 , pp. 1007-1112
    • Dehari, R.1    Kurman, R.J.2    Logani, S.3    Shih, I.M.4
  • 15
    • 58349090850 scopus 로고    scopus 로고
    • Endometriosis
    • Bulun S.E. Endometriosis. N. Engl. J. Med., 2009, 360(3), 268-279.
    • (2009) N. Engl. J. Med , vol.360 , Issue.3 , pp. 268-279
    • Bulun, S.E.1
  • 17
    • 33744466541 scopus 로고    scopus 로고
    • Antiangiogenic therapy: A universal chemosensitization strategy for cancer
    • Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer. Science, 2006, 312(5777), 1171-1175.
    • (2006) Science , vol.312 , Issue.5777 , pp. 1171-1175
    • Kerbel, R.S.1
  • 18
    • 37849000515 scopus 로고    scopus 로고
    • Angiogenesis y neoplasias
    • Khosravi, P. Angiogenesis y neoplasias. An. Med. Interna, 2006, 23(8), 355-356.
    • (2006) An. Med. Interna , vol.23 , Issue.8 , pp. 355-356
    • Khosravi, P.1
  • 19
    • 0030952289 scopus 로고    scopus 로고
    • Mechanisms of angiogenesis
    • Risau, W. Mechanisms of angiogenesis. Nature, 1997, 386(6626), 671-674.
    • (1997) Nature , vol.386 , Issue.6626 , pp. 671-674
    • Risau, W.1
  • 20
    • 0034650802 scopus 로고    scopus 로고
    • Regulation of angiogenesis via vascular endothelial growth factor receptors
    • Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 2000, 60(2), 203-212.
    • (2000) Cancer Res , vol.60 , Issue.2 , pp. 203-212
    • Veikkola, T.1    Karkkainen, M.2    Claesson-Welsh, L.3    Alitalo, K.4
  • 21
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
    • (2003) Nat. Med , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    Lecouter, J.3
  • 22
    • 37849050760 scopus 로고    scopus 로고
    • Tumoral angiogenesis: Review of the literature
    • Khosravi, P.; Fernandez, I. Tumoral angiogenesis: review of the literature. Cancer Invest. 2008, 26(1), 104-108.
    • (2008) Cancer Invest , vol.26 , Issue.1 , pp. 104-108
    • Khosravi, P.1    Fernandez, I.2
  • 23
    • 43249095919 scopus 로고    scopus 로고
    • Tumor angiogenesis
    • Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358(19), 2039-2049.
    • (2008) N. Engl. J. Med , vol.358 , Issue.19 , pp. 2039-2049
    • Kerbel, R.S.1
  • 24
    • 0029929046 scopus 로고    scopus 로고
    • Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
    • Abu-Jawdeh, G.M.; Faix, J.D.; Niloff, J.; Tognazzi, K.; Manseau, E.; Dvorak, H.F.; Brown, L.F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 1996, 74(6), 1105-1115.
    • (1996) Lab. Invest , vol.74 , Issue.6 , pp. 1105-1115
    • Abu-Jawdeh, G.M.1    Faix, J.D.2    Niloff, J.3    Tognazzi, K.4    Manseau, E.5    Dvorak, H.F.6    Brown, L.F.7
  • 25
    • 0030921126 scopus 로고    scopus 로고
    • The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer
    • Nakanishi, Y.; Kodama, J.; Yoshinouchi, M.; Tokumo, K.; Kamimura, S.; Okuda, H.; Kudo, T. The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol., 1997, 16(3), 256-262.
    • (1997) Int. J. Gynecol. Pathol , vol.16 , Issue.3 , pp. 256-262
    • Nakanishi, Y.1    Kodama, J.2    Yoshinouchi, M.3    Tokumo, K.4    Kamimura, S.5    Okuda, H.6    Kudo, T.7
  • 26
    • 33746721000 scopus 로고    scopus 로고
    • Immunolocalizations of VEGF, its receptors fl t-1, KDR and TGF-beta's in epithelial ovarian tumors
    • Inan, S.; Vatansever, S.; Celik-Ozenci, C.; Sanci, M.; Dicle, N.; Demir, R. Immunolocalizations of VEGF, its receptors fl t-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol. Histopathol., 2006, 21(10),1055-1064.
    • (2006) Histol. Histopathol , vol.21 , Issue.10 , pp. 1055-1064
    • Inan, S.1    Vatansever, S.2    Celik-Ozenci, C.3    Sanci, M.4    Dicle, N.5    Demir, R.6
  • 28
    • 4444324696 scopus 로고    scopus 로고
    • VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
    • Chen, H.; Ye, D.; Xie, X.; Chen, B.; Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol., 2004, 94(3), 630-635.
    • (2004) Gynecol. Oncol , vol.94 , Issue.3 , pp. 630-635
    • Chen, H.1    Ye, D.2    Xie, X.3    Chen, B.4    Lu, W.5
  • 29
    • 58149202145 scopus 로고    scopus 로고
    • Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma
    • Mendiola, M.; Barriuso, J.; Redondo, A. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS. One, 2008, 3, e4051.
    • (2008) PLoS. One , vol.3
    • Mendiola, M.1    Barriuso, J.2    Redondo, A.3
  • 34
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • Burger, R.A.; Sill, M.W.; Monk, B.J.; Greer, B.E.; Sorosky, J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol., 2007, 25(33), 5165-5171.
    • (2007) J. Clin. Oncol , vol.25 , Issue.33 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 36
    • 34447298651 scopus 로고    scopus 로고
    • A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
    • Micha, J.P.; Goldstein, B.H.; Rettenmaier, M.A.; Genesen, M.; Graham, C.; Bader, K.; Lopez, K.L.; Nickle, M.; Brown, J.V. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer, 2007, 17(4), 771-776.
    • (2007) Int. J. Gynecol. Cancer , vol.17 , Issue.4 , pp. 771-776
    • Micha, J.P.1    Goldstein, B.H.2    Rettenmaier, M.A.3    Genesen, M.4    Graham, C.5    Bader, K.6    Lopez, K.L.7    Nickle, M.8    Brown, J.V.9
  • 38
    • 77954499682 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study
    • Burger, R.A.; Brady, M.L.; Bookman, M.A.; Walker, J.L.; Homesley, H. D.; Fowler, J.; Monk, B. J.; Greer, B. E.; Boente, M.; Liang, S. X. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol., 2010, 28(18s), LBA1.
    • (2010) J. Clin. Oncol , vol.28 , Issue.18 s
    • Burger, R.A.1    Brady, M.L.2    Bookman, M.A.3    Walker, J.L.4    Homesley, H.D.5    Fowler, J.6    Monk, B.J.7    Greer, B.E.8    Boente, M.9    Liang, S.X.10
  • 39
    • 78650450402 scopus 로고    scopus 로고
    • ICON-7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer
    • Perren, T.; Swart, A.M.; Pfisterer, J.; Ledermann, J.; Lortholary, A.; Kristensen, G.; Carey, M.; Beale, P.; Cervantes, A.; Oza, A. ICON-7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann. Oncol., 2010, 21(8s), viii1-viii12.
    • (2010) Ann. Oncol , vol.21 , Issue.8 s
    • Perren, T.1    Swart, A.M.2    Pfisterer, J.3    Ledermann, J.4    Lortholary, A.5    Kristensen, G.6    Carey, M.7    Beale, P.8    Cervantes, A.9    Oza, A.10
  • 40
    • 80054003628 scopus 로고    scopus 로고
    • Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer
    • Kristensen, G.; Perren, T.; Qian, W. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J. Clin. Oncol., 2011, 29, LBA5006.
    • (2011) J. Clin. Oncol , vol.29
    • Kristensen, G.1    Perren, T.2    Qian, W.3
  • 41
    • 77956799700 scopus 로고    scopus 로고
    • Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium
    • Welch, S.A.; Hirte, H.W.; Elit, L.; Schilder, R.J.; Wang, L.; MacAlpine, K.; Wright, J.J.; Oza, A.M. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium. Int. J. Gynecol. Cancer, 2010, 20(5), 787-793.
    • (2010) Int. J. Gynecol. Cancer , vol.20 , Issue.5 , pp. 787-793
    • Welch, S.A.1    Hirte, H.W.2    Elit, L.3    Schilder, R.J.4    Wang, L.5    Macalpine, K.6    Wright, J.J.7    Oza, A.M.8
  • 42
    • 79952814774 scopus 로고    scopus 로고
    • A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer
    • Hainsworth, J.D.; Numnum, T.M.; Rao, G.G. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. J. Clin. Oncol., 2010, 28(18s), TPS257.
    • (2010) J. Clin. Oncol , vol.28 , Issue.18 s
    • Hainsworth, J.D.1    Numnum, T.M.2    Rao, G.G.3
  • 45
    • 58149219264 scopus 로고    scopus 로고
    • A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
    • Hirte, H.W.; Vidal, L.; Fleming, G.F. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol., 2008, 26, 5521.
    • (2008) J. Clin. Oncol , vol.26 , pp. 5521
    • Hirte, H.W.1    Vidal, L.2    Fleming, G.F.3
  • 46
    • 68449095803 scopus 로고    scopus 로고
    • A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
    • Ledermann, J.A.; Rustin, G.J.; Hackshaw, A. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J. Clin. Oncol., 2009, 27(15s), 5501.
    • (2009) J. Clin. Oncol , vol.27 , Issue.15 s , pp. 5501
    • Ledermann, J.A.1    Rustin, G.J.2    Hackshaw, A.3
  • 47
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • Biagi, J.J.; Oza, A.M.; Chalchal, H.I.; Grimshaw, R.; Ellard, S.L.; Lee, U.; Hirte, H.; Sederias, J.; Ivy, S.P.; Eisenhauer, E.A. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann. Oncol., 2011, 22(2), 335-340.
    • (2011) Ann. Oncol , vol.22 , Issue.2 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3    Grimshaw, R.4    Ellard, S.L.5    Lee, U.6    Hirte, H.7    Sederias, J.8    Ivy, S.P.9    Eisenhauer, E.A.10
  • 48
    • 46749111576 scopus 로고    scopus 로고
    • AVE 0005, AVE 005, AVE0005, VEGF Trap -Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye
    • Aflibercept
    • Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap -Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drug. R. D., 2008, 9(4), 261-269.
    • (2008) Drug. R. D , vol.9 , Issue.4 , pp. 261-269
  • 49
    • 79958828731 scopus 로고    scopus 로고
    • A randomised, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer
    • Vergote, I.B.; Oza, A.M.; Hansen, V.L. A randomised, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer. Ann. Oncol., 2010, 21(8s), 975PD.
    • (2010) Ann. Oncol , vol.21 , Issue.8 s
    • Vergote, I.B.1    Oza, A.M.2    Hansen, V.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.